Biohaven Ltd – (BHVN, +1, November 1st)
We ranked this stock +N on October 7th based on purchases of $5 million from Vladimir Coric (CEO since 2022) at $10.31, and $2.5 million from John Childs (Director since 2022) at $8.98. This entity was spun-out of Pfizer in July 2022 after Pfizer purchased Biohaven Pharmaceutical Holdings in May 2022 for $12B. BHVN just completed a secondary offering on October 25th at $10.50 in which three directors, the CEO, and the Treasurer all participated, spending a total of $53.6 million.
Since that secondary, and as the stock has moved higher, Vladimir Coric has made two additional open market purchases, spending another $2.5 million at an average price of $15. It is interesting to see the broad participation on the secondary and these follow-up purchases in the open market from the CEO.
We are increasing the rank further, from +N to +1.
If you want to have Stock of the Week with insider buying stocks information and analysis in your email, don’t forget to subscribe!
Follow us on LinkedIn and Twitter
Check our Signals Performance and if you want to know more about this Signals Service, please, email us at firstname.lastname@example.org or fill in the Contact Us form here.